Table 1 Baseline characteristics in the entire cohort and in the matched cohort
Entire cohort | Matched cohort | |||||
|---|---|---|---|---|---|---|
PDN group | Non-PDN group | P-value | PDN group | Non-PDN group | P-value | |
n = 107 | n = 37 | n = 30 | n = 30 | |||
Age, years | 64 [58–69] | 69 [61–73] | 0.016 | 65 [59–72] | 69 [61–72] | 0.452 |
Sex, male | 63 (59%) | 23 (62%) | 0.876 | 15 (50%) | 18 (60%) | 0.505 |
Body weight, kg | 57 [49–68] | 58 [49–69] | 0.703 | 56 [47–69] | 59 [47–70] | 0.365 |
Smoking, pack years | 7 [0–38] | 20 [0–47] | 0.575 | 10 [0–30] | 16 [0–34] | 0.696 |
Ever smoked | 55 (51%) | 21 (57%) | 0.145 | 17 (57%) | 17 (57%) | 0.999 |
FVC, ml | 1890 (640) | 2280 (740) | 0.003 | 2260 (700) | 2180 (740) | 0.484 |
%FVC, %predicted | 58.2 (14.2) | 71.0 (15.0) | < 0.001 | 71.5 (13.2) | 67.6 (14.0) | 0.217 |
< 50% | 31 (29%) | 3 (8%) | 0.012 | 1 (3%) | 3 (10%) | 0.617 |
%FVC decline, %predicted | ||||||
12 months before registration | 13.3 (9.5) | 5.2 (5.7) | < 0.001 | 12.0 (6.2) | 5.0 (5.3) | < 0.001 |
FEV1, ml | 1630 (530) | 1910 (580) | 0.007 | 1880 (580) | 1820 (560) | 0.565 |
%FEV1, %predicted | 64.0 (14.2) | 77.4 (14.2) | < 0.001 | 76.3 (11.7) | 73.7 (12.2) | 0.270 |
DLco, % | 44.5 (18.2) | 56.2 (23.7) | 0.005 | 56.7 (14.7) | 54.3 (25.6) | 0.658 |
Serum KL-6, U/mL | 1540 [1100–2590] | 1070 [740–1590] | 0.004 | 1420 [980–1960] | 1070 [750–1860] | 0.589 |
Serum SP-D, ng/mL | 276 [176–437] | 243 [180–317] | 0.171 | 225 [130340] | 260 [200–340] | 0.424 |
BAL lymphocyte, % | 17 [8–39] | 16 [5–39] | 0.546 | 22.9 [10.9–41.5] | 20.5 [5.5–29.8] | 0.520 |
Antigen† | ||||||
Bird-related | 78 (73%) | 31 (84%) | 0.495 | 24 (80%) | 24 (80%) | 0.999 |
Home-related | 14 (13%) | 3 (8%) | 3 (10%) | 3 (10%) | ||
Unknown | 15 (14%) | 3 (8%) | 3 (10%) | 3 (10%) | ||
Treatment | ||||||
Anti-fibrotic agent | 14 (13%) | 8 (22%) | 0.288 | 3 (10%) | 7 (23%) | 0.149 |
PFD 11, NTD 3 | PFD 4, NTD 4 | PFD 1, NTD 2 | PFD 3, NTD 4 | |||
Immunosuppressant | 49 (46%) | 0 | – | 10 (33%) | 0 | – |
CYA 33, CYC 5, TAC 11 | CYC 5, CyA 4, TAC 1 | |||||